Lymphangiogenesis and Inflammation-Looking for the "Missing Pieces" of the Puzzle

Arch Immunol Ther Exp (Warsz). 2015 Dec;63(6):415-26. doi: 10.1007/s00005-015-0349-7. Epub 2015 Jul 14.

Abstract

Several papers about lymphangiogenesis and inflammation focused on the detailed and complicated descriptions of the molecular pathways accompanying both non-tumor and tumor inflammatory-induced lymphatic vessel development. Many authors are tempted to present inflammatory-induced lymphangiogenesis in pathologic conditions neglecting the role of inflammatory cells during embryonic lymphatic vessel development. Some of the inflammatory cells are largely characterized in inflammatory-induced lymphangiogenesis, while others as mast cells, eosinophils, or plasma cells are less studied. No phenotypic characterization of inflammation-activated lymphatic endothelial cell is available in this moment. Another paradox is related to the existence of few papers regarding lymphangiogenesis inside lymphoid organs and for their related pathology. There are still several "missing pieces of such a big puzzle" of lymphangiogenesis and inflammation, with a direct impact on the ineffectiveness of the anti-inflammatory therapy as lymphangiogenesis inhibitors. The present paper will focus on the controversial issues of lymphangiogenesis and inflammation.

Keywords: Endothelial cells; Inflammation; Inflammatory cells; Lymphangiogenesis; Lymphatic vessels.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / therapeutic use
  • Carcinogenesis
  • Endothelial Cells / physiology*
  • Growth Inhibitors / therapeutic use
  • Humans
  • Inflammation / physiopathology*
  • Inflammation / therapy
  • Lymphangiogenesis*
  • Lymphatic Vessels / blood supply*
  • Lymphatic Vessels / embryology
  • Lymphatic Vessels / immunology
  • Neovascularization, Pathologic*

Substances

  • Anti-Inflammatory Agents
  • Growth Inhibitors